For chronic pain, cannabis and cannabinoid studies have mostly examined non-inhaled products, THC/CBD mouth sprays, synthetic cannabinoids, and a smaller number of inhaled or topical products. The measured relief is usually small, and the better summaries only followed people for weeks or months—not years—so the useful question is whether that trade-off fits your pain type, daily function, and other care options.
The National Center for Complementary and Integrative Health says the research has focused particularly on chronic and neuropathic pain, which is pain linked with nerve injury or damage. Cannabis is not one product: THC and CBD are different cannabinoids, and the product form matters. Our CBD ingredient profile explains the research questions around CBD, while this page separates the chronic-pain trial results by formulation and outcome.
What did chronic-pain trials actually study?
A 2021 BMJ systematic review, indexed by the U.S. National Library of Medicine, combined 32 randomized trials involving 5,174 adults. Twenty-eight trials involved chronic non-cancer pain and four involved cancer-related pain; 30 used oral products and two used topical products. Follow-up ran from one to 5.5 months. The review did not answer whether the same results apply to every pain condition, every cannabis product, or long-term use.
A separate 2018 Cochrane review focused on chronic neuropathic pain. Its 16 studies included THC/CBD oromucosal spray, nabilone, inhaled herbal cannabis, and dronabinol. Study duration was two to 26 weeks. That is the clearest condition-specific body of research in the material here, but the review rated much of its pain-relief evidence from very low to moderate quality.
| Population and pain type | Formulation compared | What was measured | Duration | What the result means | Harms and certainty |
|---|---|---|---|---|---|
| Adults with chronic non-cancer or cancer-related pain; 32 trials, 5,174 people | Mostly oral medical cannabis or cannabinoids versus placebo; two topical trials | Pain, physical function, sleep, and side effects | 1 to 5.5 months | The BMJ review found a 10% modeled increase in people reaching its minimally important pain-relief threshold; average pain improved by 0.50 cm on a 10-cm scale. | Moderate certainty for the small pain benefit. Dizziness, drowsiness, nausea, vomiting, impaired attention, and temporary cognitive impairment were more frequent than with placebo. |
| Adults with chronic neuropathic pain; 16 studies, 1,750 people | THC/CBD mouth spray, nabilone, inhaled herbal cannabis, or dronabinol versus placebo or one analgesic | At least 30% or 50% pain relief, global improvement, withdrawals, and adverse events | 2 to 26 weeks | Thirty-nine percent reached at least 30% pain relief with cannabis-based medicines versus 33% with placebo; 21% versus 17% reached at least 50% relief. | Evidence ranged from very low to moderate quality. Withdrawals for adverse events were 10% versus 5%, and the review found no long-term-risk information. |
These are group averages, not a forecast for one person. They also do not establish that a hemp gummy, a CBD-only product, a dispensary product, and a prescription cannabinoid will produce the same result. For the broader background on these compounds, see the endocannabinoid system.
How large were the measured benefits?
The 2021 BMJ review found that non-inhaled medical cannabis probably produced a small increase in pain relief compared with placebo: a modeled 10% more people reached a 1-cm improvement on a 10-cm pain scale. It found a very small improvement in physical function and a small improvement in sleep quality; it found no improvement in emotional, role, or social functioning.
For neuropathic pain, the Cochrane review found a 9-percentage-point difference for at least 30% pain relief: 39% with cannabis-based medicines and 33% with placebo. For at least 50% relief, the difference was 5 percentage points: 21% versus 17%. Those figures help set a realistic comparison: the studies measured some additional relief for some participants, not uniform or complete relief.
How durable are the results?
The available randomized-trial summaries do not tell you how benefits or harms hold up over years. The BMJ review followed participants for at most 5.5 months. The Cochrane neuropathic-pain review followed them for two to 26 weeks and specifically found no information about long-term risks in the studies it analyzed.
That short follow-up matters when you are comparing an advertised product with a longer pain-care plan. A trial result may be worth discussing, but it cannot answer whether a particular product will remain useful, how it fits your other medicines, or what happens after long-term use.
What side effects showed up in the pain studies?
In the BMJ review, non-inhaled medical cannabis was linked with small increases in temporary cognitive impairment, vomiting, drowsiness, impaired attention, and nausea. Dizziness was more frequent, especially in trials lasting at least three months. In the Cochrane neuropathic-pain review, nervous-system adverse events occurred in 61% of people using cannabis-based medicines and 29% using placebo; psychiatric disorders occurred in 17% and 5%, respectively.
The CDC’s cannabis health information says health risks can occur regardless of how cannabis is used and notes that edibles carry a risk of unintentional poisoning. It advises storing cannabis products in a locked, childproof container and out of children’s sight and reach. The NCCIH overview also notes that over-the-counter CBD products may differ from their labels and may contain contaminants, including THC.
What does federal law say about hemp, CBD, and pain products?
As of October 5, 2026, the federal baseline comes from the Agriculture Improvement Act of 2018, signed December 20, 2018. The law removed hemp meeting the statutory delta-9 THC limit of no more than 0.3% on a dry-weight basis from the Controlled Substances Act, but it preserved the FDA’s authority over cannabis-derived products under the FD&C Act. The FDA says THC and CBD products are excluded from the federal dietary-supplement definition and that FDA approval of a cannabis-derived product is not the same thing as permission for every consumer product or state sale. State rules can differ; this is information, not legal advice.
The FDA has approved individual cannabinoid drugs for specific uses, but the cannabis plant itself has not been approved for medical use. That distinction is useful when an ad blends research on prescription cannabinoids with claims about a retail CBD or hemp product.
How can you prepare a useful pain-care comparison?
Bring a short, condition-and-formulation comparison to a qualified clinician instead of trying to turn a headline into a decision. Write down:
- Your diagnosed pain condition, if you have one, and whether it has a nerve-related component.
- The exact product type being considered: CBD-only, THC-containing, a THC/CBD combination, synthetic cannabinoid, or another formulation.
- The trial outcome that matters most to you: pain score, sleep, physical function, or a specific daily activity.
- Your current medicines and any past problems with dizziness, drowsiness, attention, mood, or balance.
- The study window you are comparing against: weeks or months, rather than an assumed long-term result.
Medicare defines chronic pain as persistent or recurring pain lasting longer than three months. Its chronic pain management coverage page says Part B can cover eligible chronic-pain management and treatment services, including pain assessment, medication management, care coordination, and planning; the page explains that costs depend on coverage and other factors. That gives you another comparison point besides a product advertisement.
Before you order or use a cannabis product: ask for the exact formulation, the current label, and a product-specific lab report; compare them with the formulation actually studied; and take the list of medicines and your pain-care goals to a qualified clinician. NCCIH says not to use cannabis or cannabinoids to postpone seeing a health care provider about a medical problem.
Disclosure: This educational page contains no product recommendations or purchase links.
By TakeHempGummies.com Consumer Research Desk
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.